In active Crohn disease, risankizumab increased clinical remission and endoscopic response at 12 wk.
other
Where this comes from
- Record sourced from PubMed, PMID 36191314.
- Also identified by DOI 10.7326/J22-0080.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
D'Haens G, Panaccione R, Baert F, et al. <b>Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials.</b> Lancet. 2022;399:2015-30. 35644154.
Medical subject headings
- Crohn Disease